On the stock market since 2007, it operates in the world of health and science. It has 40 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Average growth of 14% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
The stock trades 49% below its peak. The market has trimmed its expectations for the company.
Sales run at $5.9M a year. A small number, but proof the product has real buyers.
There is $15.4M in the vault; even if every debt were paid off, $13.0M would remain.
A loss of $10.0M against $5.9M in annual sales. And on top of that, sales fell from the year before.
At the current pace of spending, the cash lasts about 1.5 years. After that, the company needs to find new money.
On our five-subject report card, SPHRY sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: SPHRY is a high-risk stock — not yet profitable, and its future rides on its product catching on.